Health Disease
Neurology Disorders | Cardiology Disorders | Respiratory Diseases | Blood Disorders | Eye Diseases | Endocrine Disorders | Reproductive Disease | Urinary Disorders | Digestive Disorders | Infectious Diseases | Skin Disorders | Immune Disorders | Home Remedies | Herbal Medicines | Drugs & Medicines | First Aid | Plastic Surgery | Depression | Yoga Health

Home :: Health Articles

Next Generation Immuno-Therapies


Acne Rosacea
Acne Types
Acupuncture Uses
Anxiety Panic Attack
Asthma in Children
Asthma in Pregnancy
Bulimia Nervosa Treatment
Dealing with Social Anxiety
Eating Disorders Treatment
Get Rid of Acne Scars
Get Rid of Gallstones
Home Remedies for Asthma Cure
Stress and Anxiety
Treating Acne Problems
Treating Anxiety Disorders
Types of Asthma
Preventing Vision Loss
Dealing with Everyday Stress
Conquering the Common Cold
Benefits of Multivitamin Supplements
Dealing with Sinusitis
Dealing with Hemorrhoids
What Causes Bad Breath
Cure Adult Acne
Dealing with Thinning Hair
Mesothelioma - Recognizing the Symptoms
Preventing Back Pain
Treadmill Workout Benefits
Preventing Osteoporosis
Treating Anemia
About High Blood Pressure
Dealing with Psoriasis
Asthma New Treatment
Acne with Accutane
Power of Aloe Vera
Benefits of Vitamin E
Dealing with Morning Sickness
About Food Allergies
What is Juvenile Diabetes
Advantages of Organic Shampoo
Contact Dermatitis Treatment
Green Tea for Weight Loss
Hypnosis to Lose Weight
Common Cold Symptoms
Treatment and Causes of Chills
How to Get Rid of Blackheads
How to Treat Burns
Home Remedies for Nail Fungus
Fibromyalgia Symptoms
Leg Cramps - Causes and Cures
How to Cure Hangover
Alcohol and Young People
How to Treat Snake Bites
Violent or Persistent Vomiting
How to Heal a Broken Bone
Benefits of Soya
What Causes Fluid Retention
How to Treat Post Nasal Drip
Ways to Grow Taller
Preschool Fitness Tips
About Stomach Fat
Knowing About Arthritis
Male Pattern Baldness Treatment
Knowing About Obesity
Information on Insomnia
How to Prevent Skin Cancer
Diabetes and Infections
Treating Lower Back Pain
Information on Lymphedema

The American Society of Clinical Oncology (ASCO) meeting that took place this year was highlighted by a discussion of a new class of immuno-therapeutic drugs that may eventually represent a massive breakthrough in cancer research. Bristol-Meyers, Squibb, Merck & Co. and Roche introduced updated findings in reference to their PD-1 and PD-L1 inhibitors. It was seen that these drugs may work in more similar means than initially expected. In addition, the prospects for the usefulness of these drugs is surmised to be in melanoma treatments, although more commercial and wide-ranging applications are also thought to be possible.

PD-L1 is an acronym for a series of proteins that may help a cancer evade a host's immune system. It is thought that by selectively targeting these proteins, a cancer will be more easily recognised by an immune system; therefore allowing an organism to more effectively destroy the invading cancerous cells. This can be seen as a possible step towards the next generation of immunotherapies. Such success has already been seen in another inhibitor produced by Bristol-Meyers and Squibb's cytoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor. The generic name for this treatment is known as Yervoy (ipilimumab).

It is particularly noted that high tumor expression of PD-L1 was directly correlated with more aggressive cancers. This suggests that if PD-L1 proteins could be suppressed by a counteractive inhibitor, the growth rates and aggressive natures of many types of cancers may be slowed significantly. This has obvious importance with more aggressive forms that have a poor prognosis for current treatments.

Another significant point of the relationship between PD-1 and PD-L1 is the fact that patients suffering from various autoimmune diseases such as Lupus presented altered levels of PD-L1 response. Thus, the inhibition of this protein through the use of PD-1 may also help combat degenerative autoimmune disorders.

As of yet, the role of PD-L1 is only beginning to be understood. Nonetheless, clinical trials of PD-L1 blockers has already begun as of April of 2013. It is hoped that through these trials, the exact function of PD-L1 can be further isolated and a new line of immuno-therapeutic drugs can be established that may present more efficacious treatment options in the near future. Companies such as Bristol-Meyers, Squibb, Merck & Co. and Roche are at the leading edge of much of this research. It is indeed true that the medical and scientific community will continue to watch the findings of these studies with great interest.